Primary Immunodeficiency clinical trials

Explore recruiting primary immunodeficiency clinical trials.

Recruiting primary immunodeficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Immunodeficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of leniolisib for immune dysregulation in patients with primary immunodeficiency

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)

Slovakia, Greece, Poland, Netherlands, Spain, Czechia +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD)

Greece, Germany, Poland, Netherlands, Denmark, Czechia +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Italy, Slovakia, Hungary, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Primary Immunodeficiency trials by city

Primary Immunodeficiency in Toronto Primary Immunodeficiency in Vancouver Primary Immunodeficiency in Montreal Primary Immunodeficiency in Calgary Primary Immunodeficiency in Edmonton Primary Immunodeficiency in Ottawa Primary Immunodeficiency in Winnipeg Primary Immunodeficiency in Quebec City Primary Immunodeficiency in Hamilton Primary Immunodeficiency in Kitchener Primary Immunodeficiency in London Primary Immunodeficiency in Halifax Primary Immunodeficiency in New York Primary Immunodeficiency in Los Angeles Primary Immunodeficiency in Chicago Primary Immunodeficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease